Metabolism Development Unit News Today

Atrasentan’s safety profile in the trial was deemed favourable, aligning with previous data.

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.

Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.

Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2...

Data at EBMT show primary endpoint met - estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline

Iptacopan achieved "improvement of anaemia never seen before with anti-C5s” in PNH, showed Novartis data presented at 2023 EBMT.

Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.